INVESTOR RELATIONS

INVESTOR OVERVIEW

INVESTOR OVERVIEW

There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary World-Leading Oncologists to Meet in Miami for Adaptive MR Image-Guided Radiotherapy Symposium
Educational Event Aims to Share Clinical Expertise and Best Practices in MR Image-guided Radiation Therapy CLEVELAND , May 23, 2018 /PRNewswire/ -- Experts in MR image-guided radiation therapy will share their experiences during an educational symposium to be held on Friday, September 28, 2018 in
Toggle Summary ViewRay to Present at the UBS Global Healthcare Conference
CLEVELAND , May 16, 2018 /PRNewswire/ -- ViewRay ® , Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer, are scheduled to present at the UBS Global Healthcare Conference in New York, NY . Event :                 UBS Global
Toggle Summary ViewRay Reports First Quarter 2018 Financial Results
Reiterates 2018 Financial Guidance CLEVELAND , May 10, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2018 . First Quarter 2018 Highlights: Total revenue of $26.2 million, primarily from 4 revenue units, up from $1.2
Toggle Summary ViewRay Announces Conference Call and Webcast of First Quarter 2018 Financial Results to be Held After Market on May 10, 2018
CLEVELAND , May 7, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2018 financial results, which will take place on Thursday, May 10, 2018 after market. ViewRay will hold a conference call on Thursday, May 10, 2018 at 4:30 p.m.

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first and only MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

Copyright 2018 © ViewRay. All rights reserved